ArticleFrontiers in pediatrics2026
Clinical phenotypes and genetic mutation analysis of 45 neonatal-onset methylmalonic acidemia.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neonatal-onset cblC-type methylmalonic acidemia combined with homocysteinemia: case report.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methylmalonic acidemia (MMA), the most prevalent organic acidemia in China, is an autosomal recessive disorder. Neonatal-onset MMA often presents with non-specific manifestation, often causing diagnostic delays. Methods: A retrospective analysis was conducted on the clinical data, laboratory findings, and genetic information of 45 neonatal-onset MMA patients admitted to the Children's Hospital Affiliated to Shandong University from October 2016 to June 2024. Results: 1) Classification: 32 combined MMA, 13 isolated MMA. Median onset: 11 days. Common manifestations: feeding difficulties (60.0%), failure to thrive (57.8%), jaundice (46.7%), respiratory distress (40.0%), impaired consciousness (28.9%). Key labs: hyperammonemia (40.0%), macrocytic anemia (33.3%), granulocytopenia (31.1%). Hydrocephalus occurred in 3/31, abnormal EEGs in 15/19. Elevated C3, C3/C0, methylmalonic acid, and methylcitric acid were diagnostic. 2) Combined MMA had significantly lower methionine, blood ammonia, and C3/C0 vs. isolated MMA. Isolated MMA showed lower leukocyte counts ( Conclusion: Neonatal-onset MMA presents with non-specific clinical phenotypes. Therefore, unexplained feeding difficulties, neutropenia, hyperammonemia, or seizures warrant prompt homocysteine, tandem MS, and urinary organic acid screening. Isolated MMA shows earlier free carnitine decline and higher ammonia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.